Breast biopsy procedures caused by false-positive diagnostic assessments in the US cost the healthcare system more than $2 billion per year. Imagio® could mitigate that by providing real-time information regarding suspicious breast masses and increased decision confidence regarding the need for invasive breast biopsies and additional exams.